{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025767","form_type":"8-K","ticker":"SFES","cik":"0000086115","company_name":"SAFEGUARD SCIENTIFICS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.773907+00:00","generated_at":"2026-06-22T10:47:28.621421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M","bullets":["Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.","Funded $1.6M convertible note in Syapse's $35M growth capital round; capital to expand real-world insights for cancer.","Trailing 12-month revenues for eight portfolio companies were $139M, up 10.7% YoY.","Repurchased 84,261 shares in Q3 at avg $4.00; YTD repurchases 453,535 shares for $2.1M.","Operating costs reduced: G&A expenses $1.4M vs $1.6M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025767","json":"https://secwatch.observer/filing/0001437749-22-025767.json","markdown":"https://secwatch.observer/filing/0001437749-22-025767.md","text":"https://secwatch.observer/filing/0001437749-22-025767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/86115/000143774922025767/0001437749-22-025767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/86115/000143774922025767/sfe20221102_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:47:28.621421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"232a560c362c769117c9f69f7c4546e05845e7c1","claim":"SAFEGUARD SCIENTIFICS INC reported three and nine months ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income.","evidence_excerpt":"o Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income of $18.3 million, or $0.88 per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/86115/000143774922025767/0001437749-22-025767-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}